Japan Blood Products Organization to build new plasma-fractionation plant in Chitose, Hokkaido
Pharma & MedicalHokkaidoreshoring
The Japan Blood Products Organization announced a plan to strengthen its production base for plasma-derived products, centred on building a new manufacturing plant on newly acquired land in Chitose, Hokkaido, at a scale of about JPY200 billion. The plan also refurbishes its two existing domestic sites (Chitose, Hokkaido and Fukuchiyama, Kyoto), doubling current plasma processing capacity. Japan's self-sufficiency rate for these products fell from near 100% in FY2015 to 59.4% in FY2025, and the expansion is aimed at restoring domestic supply.
Company
Japan Blood Products Organization
Investment
¥200B total, scale of the plan
Location
Hokkaido, Chitose
Capacity
plasma processing capacity to double (approx. 1.3 million litres/year)
Olympus has completed the new B Building at its Nagano site in Tatsuno, Nagano, consolidating development and manufacturing functions and establishing a production base for key medical-device components. Construction began in February 2025, with full operation targeted for FY2026; the building has 17,665 sqm of total floor area and a total construction cost of approximately ¥18 billion.
JGC Holdings completed the UT3 biopharmaceutical active pharmaceutical ingredient facility for Chugai Pharmaceutical Industry at its Utsunomiya plant in May 2026. The four-story facility supports clinical-trial manufacturing through initial commercial production and includes continuous-production capabilities, solar panels and other environmental features; it was handed over on May 14, 2026.
Lion has approved construction of a new pharmaceutical plant through its wholly owned Vietnamese subsidiary Merap Lion. The facility will produce prescription and over-the-counter solid-dose medicines, including tablets and granules, with operations planned to begin in the second half of 2030.
Tsumura will build a new QC building and hazardous-materials warehouse at its Ibaraki Plant in Ami, Ibaraki, to strengthen quality-testing capacity and business continuity for its kampo pharmaceutical products. Construction costs approximately ¥7 billion, designed and built by Kajima Corporation, with completion planned for mid-April 2028.
HOYA Lens Brazil plans to rationalize and expand manufacturing equipment for healthcare-related products at its Rio de Janeiro facility. The project is funded internally, with a total planned investment of JPY 1.027 billion; no construction schedule or capacity increase is disclosed.